盐酸戊乙奎醚对慢性阻塞性肺病病人呼吸力学参数的影响

目的研究应用盐酸戊乙奎醚对慢性阻塞性肺病(chronic obstructive pulmonary dis-ease,COPD)病人气管内插管应用呼吸机后呼吸力学参数的影响。方法COPD病人66例随机均分为两组:盐酸戊乙奎醚组(Ⅰ组):气管插管应用呼吸机前静注盐酸戊乙奎醚1mg;对照组(Ⅱ组):不给予任何支气管扩张药物。分别观察并监测气管内插管应用呼吸机后1、4和6h的呼吸力学参数(气道压力、气道阻力和胸肺顺应性)。结果Ⅰ组各个时间点的气道峰压、气道平台压以及气道阻力明显低于Ⅱ组(P<0.05),而胸肺顺应性明显高于Ⅱ组(P<0.05)。结论盐酸戊乙奎醚可明显降低COPD病人气管内插管后的气道压力和气道阻力,增加胸肺顺应性。     

麻醉前应用盐酸戊乙奎醚对心率和血压的影响

盐酸戊乙奎醚(penehyclidine hydrochloride,长托宁)目前在麻醉前应用的报道甚少.本文以氢溴酸东莨菪碱(以下简称东莨菪碱)作比对,观察麻醉前肌注长托宁后患者心率和血压的变化.     

盐酸戊乙奎醚对全麻患者肺胸顺应性的影响

目的研究盐酸戊乙奎醚对全麻机械通气患者肺胸顺应性(Comp)的影响。方法40例ASAⅠ级拟行气管插管全身麻醉的择期手术患者,随机均分为观察组和对照组。所有患者诱导前静脉注射咪唑安定0.03 mg/kg,以丙泊酚2～2.5 mg/kg、芬太尼3μg/kg、维库溴铵0.1 mg/kg静脉诱导;采用压力控制机械通气使呼气末二氧化碳分压(PETCO2)维持在正常范围;丙泊酚、维库溴铵持续输注维持麻醉。诱导后20 min,观察组静脉给予盐酸戊乙奎醚0.02 mg/kg,对照组给予生理盐水。监测给药前(T0)、给药后5 min(T5)、10 min(T10)、20 min(T20)、30 min(T30)的HR、MAP、SpO2、PETCO2、潮气量(VT)、Comp和T0、T30时的血气分析。结果两组HR、MAP差异无统计学意义。T5、T10、T20、T30时观察组VT、Comp均明显高于T0时(P<0.05或P<0.01),T20、T30时观察组的VT明显高于对照组(P<0.05)。结论对于全麻患者,盐酸戊乙奎醚可以扩张支气管,改善Comp且对血流动力学无明显影响。     

静脉注射盐酸戊乙奎醚对腹腔镜手术患者呼吸功能的影响

目的:评价气腹前静脉注射盐酸戊乙奎醚对腹腔镜胆囊手术患者呼吸功能的影响。方法:择期全麻下拟行腹腔镜胆囊手术患者50例,ASA分级Ⅰ或Ⅱ级,年龄35～64岁,采用随机数字表法,将患者随机分为两组(n=25)静脉注射盐酸戊乙奎醚组:气腹前15mi n静脉注射盐酸戊乙奎醚1mg(用生理盐水稀释至2ml)和对照组:静脉注射等容量生理盐水。麻醉诱导:两组均TCI异丙酚(血浆靶浓度3μg/ml),静脉注射瑞芬太尼1μg/kg和顺苯阿曲库铵0.15mg/kg行气管插管。麻醉维持:TCI异丙酚,血浆靶浓度为2μg/ml,TCL瑞芬太尼(血浆靶浓度2～4ng/kg),静脉输注顺阿曲库铵1.2ug.kg-1`.mi n-1。维持BIS45-50。分别于气腹前15mi n给药前即刻(T0)、气腹后即刻(T1)、气腹15mi n(T2)和气腹放气后15mi n(T3)时记录肺动态顺应性、气道峰压和监测血气指标。结果:与T0比较,戊乙奎醚组T1-3时肺动态顺应性(Cd)及气道峰压(Ppeak)差异均无统计学意义(P>0.05),而对照组T1-2时Cd降低,Ppeak升高(P<0.05),于T3与时恢复至T0水平(P>0.05),两组PETCO2升高(P<0.05);与对照组比较,戊乙奎醚组T1-2时Cd升高,Ppeak降低(P<0.05)。结论:在腹腔镜胆囊手术中,气腹前静脉注射盐酸戊乙奎醚可改善二氧化碳人工气腹引起的气道压升高和肺顺应性降低,增加气道通气功能。     

吸入和静脉应用盐酸戊乙奎醚对油酸诱导大鼠急性肺损伤的影响

目的观察雾化吸入和静脉应用盐酸戊乙奎醚对油酸诱导大鼠急性肺损伤(ALI)的影响。方法采用静脉注射油酸复制ALI大鼠模型。将40只SD大鼠随机均分为四组:空白对照组(Ⅰ组)、ALI组(Ⅱ组)、盐酸戊乙奎醚雾化吸入组(Ⅲ组)和盐酸戊乙奎醚静脉注射组(Ⅳ组)。每隔60分钟记录大鼠BP、肺动脉压(PAP),并检验动脉及混合静脉血气。注射油酸240min后检测支气管肺泡灌洗液(BALF)蛋白定量、肺髓过氧化物酶(MPO)活性。结果Ⅲ、Ⅳ组较之Ⅱ组能够缓解由注射油酸引起的PAP升高和PaO2/FiO2下降,Ⅲ组缓解更为明显(P<0.05)。Ⅲ、Ⅳ组BALF蛋白定量、白细胞计数和肺MPO活性均比Ⅱ组降低,Ⅲ组降低更为明显(P<0.05)。结论盐酸戊乙奎醚雾化吸入较静脉注射更能缓解油酸引起的ALI。     

盐酸戊乙奎醚和阿托品对老年患者心率变异性及心率影响的比较

阿托品的抗胆碱样作用能抑制腺体分泌而广泛应用于麻醉前准备,但由于其抗M2受体作用常引起心率(HR)加快。盐酸戊乙奎醚注射液是一种新型的抗胆碱样药,研究证实它对M1、M3受体有高度选择性而对M2受体无明显作用。但对患者心率变异性(HRV)的影响尚无定论。本研究拟比较盐酸戊乙奎醚和阿托品对老年患者HRV及HR的影响,为盐酸戊乙奎醚的麻醉前应用提供临床依据。     

盐酸戊乙奎醚对妇科腹腔镜手术患者术中肺通气功能的影响

目的 研究术前应用盐酸戊乙奎醚是否可以改善妇科腹腔镜患者术中肺通气功能,并观察其对循环指标的影响.方法 选择择期腹腔镜下子宫切除或子宫肌瘤剔除术患者42例,采用信封法随机分为2组(每组21例),试验组(P组)在气管插管后10 min缓慢静注盐酸戊乙奎醚20 μg/kg,对照组(N组)静注生理盐水.记录给药前(T0)、气腹后5(T1)、30(T2)、60(T3)、90 min(T4)时患者心率(HR)、收缩压(SBP)、舒张压(DBP)、血氧饱和度(SpO2),呼气末二氧化碳分压(PETCO2)、肺顺应性(Compl)、气道阻力(Raw)、气道峰压(Ppeak)、平台压(Pplat)与术中尿量、手术时间、输血输液量. 结果 给药前(T0)两组患者肺功能各项指标差异无统计学意义(P＞0.05);气腹后两组患者与T0时比较Ppeak、Pplat、Raw升高而Compl下降,T1、T2、T3、T4时P组患者Raw分别为(14.8±1.4)、(14.6±1.6)、(14.6±1.3)、(14.4±1.2) cm H2O·L-1·s-1(1 cm H2O=0.098 kPa),而N组分别为(16.2±1.6)、(16.1±1.8)、(16.1±1.9)、(16.1±1.7) cm H2O·L-1·s-1,P组皆低于N组(T1:P=0.004,T2:P=0.01,T3:P=0.005,T4:P=0.001),而Compl测量值在T3、T4两个时点P组为(30.2±3.5)、(29.9±3.6)ml/cm H2O,高于N组的(27.3±4.8)、(27.2±4.1) ml/cm H2O(T3:P=0.033,T4:P=0.031).与T0时比较,两组患者术中HR明显下降(P=0.000),SBP、DBP、SpO2与T0时比较差异无统计学意义(P＞0.05). 结论 妇科腹腔镜手术术前应用盐酸戊乙奎醚可有效改善患者气腹后肺通气功能,降低气道阻力,提高肺顺应性,对血流动力学无明显影响.     

盐酸戊乙奎醚对心脏手术围术期应激反应的影响

目的观察盐酸戊乙奎醚对围术期应激反应的影响。方法 40例心肺转流（CPB）下行心脏瓣膜置换术患者,随机均分为盐酸戊乙奎醚组（P组）和对照组（C组）。P组CPB前10 min颈内静脉注射盐酸戊乙奎醚0.05 mg/kg,C组给予等容量生理盐水。分别于CPB前（T₁）、主动脉开放10 min（T₂）、停CPB即刻（T₃）、术后2 h（T₄）、6 h（T₅）、18 h（T₆）采集中心静脉血,测定血浆白细胞介素-6（IL-6）、白细胞介素-10（IL-10）水平,并进行静脉血气分析和血糖、血乳酸监测。结果 T₂、T₃、T₅时P组血糖和乳酸浓度明显低于C组（P<0.05）,T₃～T₅时P组血浆IL-6水平明显低于C组（P<0.05）。结论预先给予盐酸戊乙奎醚0.05 mg/kg可减轻围CPB期应激反应,可能与整体调控神经-内分泌-免疫系统使其趋于平衡有关。     

盐酸戊乙奎醚术前应用对患者呼吸功能的影响

目的探讨盐酸戊乙奎醚术前用药对全麻下患者呼吸功能的影响。方法气管内插管全麻患者80例,ASAⅠ或Ⅱ级,随机均分为两组,插管后10 min分别静脉推注盐酸戊乙奎醚0.01mg/kg（P组）或东莨菪碱0.006mg/kg（S组）。监测给药前、给药后5、10、20、30min呼吸力学参数变化和给药前、给药后30min的动脉血气分析结果。结果给药后10、20、30min P组胸肺顺应性（Comp）明显高于给药前（P<0.05）,且在给药后20、30min时明显高于S组（P<0.05）。两组给药前、给药后30min PaO₂和氧合指数（OI）差异无统计学意义。结论盐酸戊乙奎醚术前应用可明显降低全麻气管插管后气道阻力及气道压力,增加Comp,改善肺功能。     

盐酸戊乙奎醚用于重度有机磷中毒的救治

目的比较盐酸戊乙奎醚与阿托品在救治重度有机磷中毒中的疗效。方法以作者及所在科室既往救治的重度有机磷中毒患者作为对照组,选择新就诊的重度有机磷中毒患者作为治疗组,以盐酸戊乙奎醚替代阿托品作为抗胆碱药物,比较两组的治愈率、病死率、严重并发症的发生率及严重并发症的病死率等。结果对照组总治愈率为80·0%,总病死率为20·0%,中毒治疗时间平均为8·3d,严重并发症的发生率为73·3%,严重并发症的病死率为27·3%。治疗组总治愈率为94·7%,总病死率为5·3%,中毒治疗时间平均为10·2d,严重并发症发生率为47·4%,严重并发症的病死率为11·1%。两组间治愈率、总病死率及严重并发症发生率有显著性差异(P<0·05)。两组间严重并发症的病死率及平均中毒治疗时间上无显著性差异。结论与阿托品相比,盐酸戊乙奎醚能进一步减少严重并发症的发生,降低死亡率,提高治愈率。     

静脉注射盐酸戊乙奎醚或多索茶碱对慢性阻塞性肺疾病患者非开胸手术时呼吸力学的影响

目的 评价静脉注射盐酸戊乙奎醚或多索茶碱对慢性阻塞性肺疾病(COPD)患者非开胸手术时呼吸力学的影响.方法 择期行非开胸手术的COPD患者135例,年龄55～86岁,体重44～78 g,ASA分级Ⅱ或Ⅲ级,采用随机数字表法,将其随机分为3组(n=45):对照组(c组)、盐酸戊乙奎醚组(P组)和多索茶碱组(D组).麻醉诱导:静脉注射芬太尼4μg/kg、异丙酚1.5 mg/kg和顺阿曲库铵0.2 mg/kg,气管插管后行机械通气,维持PErCO2 40mm Hg.气管插管后5 rin时P组静脉注射盐酸戊乙奎醚0.01 mg/kg,D组静脉注射多索茶碱4 mg/kg,C组静脉注射等容量生理盐水.麻醉维持:静脉输注异丙酚5mg·kg-1·h-1和顺阿曲库铵0.2 mg·kg-1·h-1,间断静脉注射芬太尼.术中维持听觉诱发电位指数15～20.于给药前即刻、给药后30、45和60min时,记录气道峰压、气道平台压、肺顺应性和气道阻力.结果 与C组比较,给药后各时点P组和D组气道峰压、气道平台压和气道阻力均降低,肺顺应性升高(P＜0.05);P组和D组各时点呼吸力学各参数比较差异无统计学意义(P＞0.05).结论 静脉注射盐酸戊乙奎醚和多索茶碱均可改善COPD患者非开胸手术时的呼吸力学,有利于通气.

Abstract：

Objective To investigate the effects of intravenous penehyclidine hydrochloride or doxofylline on respiratory mechanics during non-thoracotomy in patients with chronic obstructive pulmonary disease (COPD).Methods One hundred and thirty-five ASA Ⅱ or Ⅲ patients with COPD, aged 55-86 yr, weighing 44-78 kg,scheduled for elective non-thoracotomy under general anesthesia, were randomly divided into 3 groups ( n = 45 each): control group (group C), penehyclidine hydrochloride group (group P) and doxofylline group (group D).Anesthesia was induced with fentanyl 4 μg/kg, propofol 1.5 rg/kg and cis-atracurium 0.2 mg/kg. The patients were tracheal intubated and mechanically ventilated. PETCO2 was maintained at 40 mm Hg. At 5 rin after tracheal intubation, penehyclidine hydrochloride 0.01 mg/kg was injected intravenously in group P, and doxofylline 4 mg/kg was injected intravenously in group D. The equal volume of normal saline was injected intravenously in group C. Anesthesia was maintained with propofol 5 mg· kg- 1 · h- 1, eis-atracurium 0.2 mg· kg- 1 · h- 1, and intermittent iv boluses of fentsnyl. The auditory evoked potential index was maintained at 15-20 during operation. The peak airway pressure, airway plateau pressure, lung compliance and airway resistance were recorded immediately before administration, and at 30, 45 and 60 rin after administration. Results Compared with group C, the peak airway pressure, airway plateau pressure and airway resistance were significantly decreased, while the lung compliance was significantly increased at each time point after administration in groups P and D ( P ＜ 0.05 ). There was no significant difference in the parameters of respiratory mechanics at each time point between group P and group D ( P ＞ 0.05). Conclusion Both intravenous penehyclidine hydrochloride and doxofylline can improve respiratory mechanics during non-thoracotomy in patients with COPD.     

Thermogenic effect of bronchodilators in patients with chronic obstructive pulmonary disease

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) are frequently malnourished and have increased resting energy expenditure (REE). An increase in the work of breathing is generally considered to be the main cause of this hypermetabolism, but other factors may also be implicated. Bronchodilators may decrease the work of breathing by reducing airway obstruction, but beta 2 adrenergic agents have a thermogenic effect. The aim of this study was to determine the effect of salbutamol and ipratropium bromide administration on REE in patients with COPD. METHODS: Thirteen patients (10 men) of mean (SD) age 68.3 (7.3) years and forced expiratory volume in one second (FEV1) 39.0 (17.0)% predicted were studied on three consecutive days. The REE was measured by indirect calorimetry at 30, 60, 120, and 180 minutes after double blind nebulisation of either salbutamol, ipratropium bromide, or placebo in random order. RESULTS: FEV1 increased both after salbutamol and after ipratropium. The difference in the mean response between salbutamol and placebo over 180 minutes was +199 ml (95% CI +104 to +295). The difference in mean response between ipratropium and placebo was +78 ml (95% CI +2 to +160). REE increased after salbutamol but was not changed after ipratropium. The difference in mean response between salbutamol and placebo was +4.8% of baseline REE (95% CI +2.2 to +7.4). Heart rate increased after salbutamol but not after ipratropium. The difference in the mean response between salbutamol and placebo was +5.5 beats/ min (95% CI +2.6 to +8.4). CONCLUSION: Salbutamol, but not ipratropium bromide, induces a sustained increase in the REE of patients with COPD despite a reduction in airway obstruction.


     

Exercise in patients with chronic obstructive pulmonary disease

Patients with chronic obstructive pulmonary disease (COPD) may incur exercise limitation by any one or combination of disturbances in breathing mechanics, oxygen transport, respiratory muscle metabolism or respiratory regulation and sensation. In spite of the increased ventilation demand/capacity ratio in these patients, the relationship between breathing mechanics, respiratory muscle fatigue, the adequacy of alveolar ventilation and the development of exertional dyspnoea is neither clearly defined nor predictable from data obtained with the patient at rest. The issue of oxygen transport during exercise has been complicated by confusion between arterial hypoxia and inadequate volume of oxygen transported to the tissues, which frequently may differ qualitatively and quantitatively. The cardiac output response to exercise in patients with COPD is therefore critical in determining oxygen transport. This response is also impossible to predict from resting lung mechanics, pulmonary arterial blood pressure, arterial oxygen tension or clinical disease profile. Without exercise testing, which includes measurement of all the variables mentioned, it is impossible to define clearly the cause of exercise-induced symptoms in patients with COPD. Exercise training with and without supplemental oxygen has been shown to improve exercise tolerance in these patients, but the precise mechanism of this improvement remains obscure.     

The effect of volatile anesthetics on respiratory system resistance in patients with chronic obstructive pulmonary disease

We examined the effect of isoflurane and sevoflurane on respiratory system resistance (Rmin,rs) in patients with chronic obstructive pulmonary disease (COPD). The diagnosis of COPD rests on the presence of airway obstruction, which is only partially reversible after bronchodilator treatment. Ninety-six consecutive patients undergoing thoracic surgery for peripheral lung cancer were enrolled. They were divided into two groups: preoperative forced expiratory volume in 1 s/forced vital capacity ratio <70% or >70%. Rmin,rs was measured after 5 and 10 min of maintenance anesthesia by using the constant flow/rapid occlusion method. Maintenance of anesthesia was randomized to thiopental 0.30 mg . kg(-1) . min(-1) or 1.1 minimum alveolar anesthetic concentration end-tidal isoflurane or sevoflurane. Eleven patients were excluded: two because anesthesia was erroneously induced with propofol and nine because of an incorrect tube position. Maintenance with thiopental failed to decrease Rmin,rs, whereas both volatile anesthetics were able to decrease Rmin,rs in patients with COPD. The percentage of patients who did not respond to volatile anesthetics was larger in those with COPD as well. In conclusion, we have demonstrated that isoflurane and sevoflurane produce bronchodilation in patients with COPD.     

Cough threshold in patients with chronic obstructive pulmonary disease

BACKGROUND: Cough is an important symptom of patients with chronic obstructive pulmonary disease (COPD). The cough threshold to citric acid and capsaicin in patients with COPD and in normal volunteers was measured, as well as bronchial hyperresponsiveness to methacholine. METHODS: Nineteen patients with COPD and 22 controls were recruited. Subjects underwent a methacholine bronchoprovocation test and a cough challenge to citric acid and capsaicin. RESULTS: The log citric acid cough threshold D2 (concentration causing two coughs) was significantly lower in patients with COPD (mean 2.17 versus 2.56, mean difference (95% CI) 0.39 (0.04 to 0.74), p = 0.02) but not for capsaicin cough D2 (0.66 versus 0.8, p = 0.41). Sixteen patients with COPD had bronchial hyperresponsiveness which was correlated with baseline FEV1 (r = 0.6, p = 0.01, 95% CI 0.15 to 0.84). CONCLUSIONS: Patients with COPD have a lower cough threshold to citric acid, possibly due to a differential effect of cigarette smoke on citric acid sensitive cough receptors.     

Exercise in patients with chronic obstructive pulmonary disease.

Sporadic visits to the local doctor followed sometimes by changes in oral and inhaled bronchodilators and occasionally by the addition of steroids frequently does little to significantly improve symptoms and function in the disabled patient with COPD. As in other chronic diseases, the management of these patients is facilitated by a team approach in conjunction with general rehabilitation principles. The rationale and practical implementation of such a programme has recently been outlined by the American Association of Cardiopulmonary Rehabilitation. These are multifaceted programmes but a key component, as outlined above, is exercise training. In this brief review the various approaches available have been described. Controversy still reigns regarding the optimal modes of training and there are important differences among the several approaches. Two main groups can be delineated. One emphasises the detailed definition of the impaired physiology with therapeutic measures targeted to specific defects. There is good documentation that, conversely, unstructured programmes that use treadmill and free range walking and cycling also improve endurance for walking. Upper extremity training is of additional benefit. Programmes with as little as three sessions per week of 1-2 hours of low intensity activity have achieved success so we know that simple programmes can be helpful. Moreover, without the necessity for complex testing and training methods these programmes can be implemented with relatively low costs. Future investigations to examine the relationship between improved exercise capacity for walking and arm exercise on the one hand, and the ease of performance of activities of daily living on the other, will help to reinforce the effectiveness of exercise programmes.     

盐酸戊乙奎醚对梗阻性黄疸患者血浆sTM和vWF水平的影响

目的研究盐酸戊乙奎醚对梗阻性黄疸患者全身性血管内皮细胞(VEC)急性损伤的保护作用。方法择期行上腹部手术患者90例,患者随机均分为三组,术前分别肌注盐酸戊乙奎醚0.02mg/kg(P组)、东莨菪碱0.3mg(S组)和生理盐水(C组)。分别于术前、手术结束、术后6、24、72h采血动态监测三组患者血浆可溶性血栓调节蛋白(sTM)和血管性假血友病因子(vWF)的变化。结果三组患者血浆sTM和vWF水平在手术结束、术后6、24h时均高于术前(P<0.01),但P组和S组低于C组(P<0.01);P组又明显低于S组(P<0.05)。结论盐酸戊乙奎醚与东莨菪碱均可减轻梗阻性黄疸导致的VEC损伤,而盐酸戊乙奎醚作用更加明显。     

盐酸戊乙奎醚对急性百草枯中毒所致大鼠肺间质纤维化的影响

目的研究盐酸戊乙奎醚（penehyelidine hydrochloride,PHC）对急性百草枯（paraquat,PQ）中毒所致大鼠肺间质纤维化（pulmonary interstitial fibrosis,PIF）的影响。方法SD雄性大鼠48只,采用随机数字表法分为4组：对照组（Con组）、模型组（Mod组）、PHC治疗组（PHC组）、地塞米松（dexamethasone,Dex）治疗组（Dex组）;每组再分为第7天和第22天两个亚组,每组6只。腹腔注射质量分数20％PQ溶液（18me／ks,生理盐水稀释至1ml）的方法制备大鼠PQ中毒模型;Con组腹腔注射Iml生理盐水。染毒后30min,PHC组和Dex组大鼠分别向其腹腔注射PHC（0．1mg／kg）和Dex（3mg／kg）,药物用生理盐水稀释至1ml,每24h重复1次;Con组和Mon组在对应时间点腹腔注射1ml生理盐水。于染毒后第7天和第22天处死实验动物,检测动脉血氧分压（partial pressure of oxygen in artery, PaO2）和动脉血二氧化碳分（partial pressure of carbon dioxide inartery,PaCO2）,测定肺组织汹干重比（wet／dryratio,W/D）,检测肺组织转化生长因子-β1（transforming growth factor-β1,TGF-β1）的表达,苏木精伊红（hematoxvlin-eosin,HE）、Masson染色观察肺组织病理形态学变化。结果与Con组比较,Mod组、PHC组和Dex组大鼠第7天／第22天Pa02显著降低[（79±6）mmHg/（78±8）mmHg vs（39±6）mmHg（44±5）mmHg、（46±4）mmng／（52±5）mmHg、（54±6）mmHg/（60±6）mmHg（1mmng=0．133kPa）],PaC02显著增加[（44土7）mmHg/（45±7）mmHg vs（92±5）mmHg／（82±4）mmHg、（84±8）mnlH±（73±8）mmHg、（75±7）mmH±（65±7）mmHg],肺组织W／D显著升高[（2．60±0．25）／（2．58±0．22）VS（5．67±0．61）／（4．57±0．39）、（4．25±0．44）／（3．85±0．34）、（3．69±0．40）／（3．40±0．28）],TGF-β1表达显著增加[（136±7）／（140±7）VS（215±23）／（322±29）、（193±11）／（246±16）、（186±11）1（214±14）];与Mon组比较,PHC组和Dex组大鼠PaO2升高、PaC02降低,肺W／D和TGF—β1表达降低,差异均有统计学意义（P〈0．05或P〈0．01）;PaO2、PaCO2和肺W／D在第7天变化更明显,TGF-β1表达增加在第22天更明显;第7天组织形态学以急性肺炎性改变为主、第22天以PIF为主,PHC组和Dex组大鼠肺组织炎性侵润和PIF程度较Mon组轻。结论PHC能抑制肺组织TGF—β1的表达,减轻急性PQ中毒大鼠肺组织的炎性侵润和PIF。